PubMed Health⌕ Search

Biomedical subjects

A Moretti

Publications and source records attributed to A Moretti.

At least 55 records · Page 3Linked to original sources
PubMed1984

[Effect of maternal anxiety (unrest) on the health status of the fetus].

The aim of our study was to clarify the question, to what extent the anxiety of the gravida during gestation is capable to influence the fetal condition.--For that reason, besides of a statistical analysis of a standardized interview the basal heart frequency and the reaction in a non-stress CTG over 20 min has been examined. The data of 101 women between the 36th and 42nd week of gestation were included. The age of our patients ranged from 20 to 30 years.--For assessment of the degree of anxiety we used the STAI X-1 test (questionnaire for self-assessment of anxiety as condition and characteristically personal property, resp.). Cases of pathologic gestation were excluded by history and a carefully clinical examination. No significant correlations between the level of anxiety and fetal condition could be demonstrated. We detected only a slight tendency of decreasing heart-rate variability and increasing frequency of accelerations in the CTG, as well as an increase of active fetal movements with a raising maternal level of anxiety.

Adult↗
PubMed1983

Effect of protein concentration and blood clots on the "in vitro" anti-Pseudomonas aeruginosa activity of cefoperazone.

The effect of the protein content in the medium and blood clots on the anti-Pseudomonas aeruginosa activity of cefoperazone was studied and its activity against strains of the bacteria in the blood clots investigated. Medium protein content, blood clots and the localization of the microorganism all appeared to effect the antibacterial activity of cefoperazone: the therapeutic implications of these findings are briefly discussed.

Blood Coagulation↗
PubMed1981

Suction skin blister, skin window, and skin chamber techniques to determine extravascular passage of cefotaxime in humans.

We report the results obtained in comparative study on the extravascular passage of cefotaxime, employing three different methods: suction skin blister, skin window, and skin chamber. Applying the skin blister method in two different ways, we also studied the influence that suction pressure and time lapse between blister formation and antibiotic injection had on the results obtained in order to standardize the method and establish repeatability of the results. Using the skin chamber method, we studied the influence that the different protein contents in the fluid used to fill the skin chamber had on extravascular concentrations.

Adolescent↗
PubMed1979

[Metabolic and neurochemical effects of nicergoline on the central nervous system. A review of the experimental studies (author's transl)].

The effects of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol(5-bromonicotinate) (nicergoline, Sermion) on the energy metabolism in the animal CNS during and after cerebral hypoxia and ischemia have been studied by various authors by different methodological approaches. For this purpose both electrophysiological (EEG and cortically evoked potentials) and neurochemical parameters (adenylates, creatinphosphate and some intermediates of glycolysis and Krebs cycle) were analysed in dogs and cats. These studies concordantly show that nicergoline exerts a favourable activity during the post-hypoxic and post-ischemic period. In fact the recovery of the electrophysiological and neurochemical parameters is always more rapid in nicergoline-treated animals than in controls. The effects of nicergoline on the EEG pattern, on the energy potential and citrate concentration are particularly interesting.

Animals↗
PubMed1979

[A review of pharmacological studies on nicergoline].

10-Methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) shows a strong alpha-blocking activity both in vitro and in vivo. Various studies (dog, cat, rabbit, rat, mouse, guinea-pig) show that nicergoline affects only slightly blood pressure and heart rate and increases the blood flow in brain and hind limb without affecting the splanchnic and aortic flow in normal animals. Nicergoline does not interfere with CNS functions unless applied in high doses. It stimulates the muscle oxidative metabolism and function and lacks any emetic and hallucinogenic activity. Its acute and chronic toxicity in different animal species is very low.

Adrenergic alpha-Antagonists↗
PubMed1979

[Cerebral enzymatic activities related to energy transduction processes. A model for the evaluation of pharmacological changes in the brain of the adult rat].

A test model of studying the effects of chronic pharmacological treatment on cerebral metabolism related to energy transduction was developed. The most useful biochemical parameters were the cerebral enzymatic activities related to the glycolytic pathway (lactate dehydrogenase), the Krebs' cycle (citrate synthetase and malate dehydrogenase) and the electron transfer chain (total NADH-cytochrome c reductase and cytochrome oxidase). The model is based on the natural growth-dependent changes occurring in the rat during aging (from 10 to 60 weeks of life). As test drug, 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) was administered daily for three periods of 16 weeks each (10-26, or 28-44, or 44-60 weeks of life) by two different administration routes (oral and i.p.), and at two different dose levels: oral 1 or 4, i.p. 0.25 or 1 mg/kg. Biochemical data were obtained blindly after 4, 8, 12 and 16 weeks of treatment. The drug tested exerted different effects which were dependent on the various administration periods and the administration routes. No dose-effect relationship was established.

Animals↗